Skip to content

A Study on the Eye Safety of Baby Shampoo, Head-to-Toe Wash, and Baby Soap in Adults

A Study for in-use Ocular Safety (Eye Instillation) Evaluation of a Baby shampoo, Head-to-toe wash, Baby soap in Healthy Adult Male and Female Participants. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/108973
Enrollment
24
Registered
2026-04-21
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: R For Rabbit Biomimic Shampoo: Marketed by: R For Rabbit Baby Products Pvt Ltd Route of Application: Topical Mode of Usage: Apply an adequate amount of shampoo to wet hair and scalp. Ge

Sponsors

R For Rabbit Baby Products Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Ages 18-65 years both inclusive. 2.Sex: Males and non-pregnant or non-lactating females 3.Females with self-reported negative pregnancy test. 4.The study Participant is in general good health and has both eyes. 5.Understand the test procedures and agree to adhere to study requirements, instructions and procedures. 6.Pass a general eye evaluation as assessed by trained clinicians/ophthalmologists. 7.Pass an eye sting evaluation using isotonic saline. 8.Study participants are willing to refrain from using any eye drops on the day of the study.

Exclusion criteria

Exclusion criteria: 1. Currently or within the last 2 weeks using eye drops (such as saline solutions, Netra-Prabha, Drasty, etc). 2. Have worn contact lenses during the study period. (12 months). 3. Have any of the following conditions or factors that may affect the interpretation of the test results, including but not limited to, diabetes (controlled or uncontrolled), currently pregnant, or currently lactating or have lactated within the last 4 months. 4. Have participated in a study with the eyes as the target area within 6 weeks of the start of the study. 5. Be participating in any other study concurrently. 6. Be involved in any aspect of study administration, i.e., evaluating applying products, etc. 7. Have a history of sensitivity and/or adverse reactions to preparations intended for the eyes. 8. Ever had any eye conditions such as glaucoma, cataracts, exophthalmos (protuberance of the eye), etc. 9. Subject currently having any eye infections or irritation. 10. The subject is having any sensitivity to eye make-up. 11. Currently have any eye infections or irritation including blepharitis, general lid inflammation, conjunctivitis, or an eye discharge within two weeks of the study. 12. Ever had any eye surgery (including Lasik, laser eye surgery). 13. Currently using any topical medications on the face or any medications intended for the eyes. 14. Be wearing any facial makeup, including false eyelashes, on the day of the study visits. 15. Consume any alcoholic beverages during the days of the study. 16. Have taken antihistamines (including those in cold tablets, OTC allergy medications, decongestants and inhalants) or analgesics (including aspirin or other over-the-counter analgesics) on the days of the study. 17. Have any other condition or factor that the Investigator or Ophthalmologist believes may affect the stinging or tearing response or the interpretation of the results. 18. Currently taking any prescription pain medications. 19. Have smoked within 1 hour during the study visit.

Design outcomes

Primary

MeasureTime frame
1.To assess the ocular irritation and stinging/discomfort effect of the test product as compared to control with both subjective and objective evaluations before and after instillation. 2.To assess the visual effect i.e., degree of inflammation of bulbar conjunctiva, palpebral conjunctiva, and lacrimation of test product as compared with the control before and after instillation. 3.To assess the safety and efficacy of test products by subjective perception questionnaire after instillation. Timepoint: Baseline and post instillation at 30 seconds, 15 minutes and 60 minutes on day 01

Secondary

MeasureTime frame
NATimepoint: NA

Countries

India

Contacts

Public ContactDr Maheshvari Patel

NovoBliss Research Private Limited

dr.nayan@novobliss.in07948983895

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026